The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 appendix a supplementary data to this article can be found online at https://doi org/10 1016/j euros2023 09 013 ."

"

 Financial disclosures: Eric Rovner certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Roger Dmochowski has served as an advisor for AbbVie. Christopher Chapple has served on an advisory board and as a researcher for Allergan; has served as an author for Astellas, B Braun, and Ferring, as a speaker for Allergan, Astellas, and Urovant, and as a consultant for Proverum and Ferring; and is joint holder of a patent for a new mesh material in development. Jennifer Gruenenfelder has served on a speaker bureau for AbbVie. Jun Yu, Anand Patel, and Mariana Nelson are employees of AbbVie and may hold AbbVie stock. Eric Rovner has served on an advisory board for Allergan/AbbVie and as a study participant and central urodynamics reader for prior Allergan onabotulinumtoxinA studies. Financial disclosures :"

"

Financial disclosures: Eric Rovner certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Roger Dmochowski has served as an advisor for AbbVie. Christopher Chapple has served on an advisory board and as a researcher for Allergan; has served as an author for Astellas, B Braun, and Ferring, as a speaker for Allergan, Astellas, and Urovant, and as a consultant for Proverum and Ferring; and is joint holder of a patent for a new mesh material in development. Jennifer Gruenenfelder has served on a speaker bureau for AbbVie. Jun Yu, Anand Patel, and Mariana Nelson are employees of AbbVie and may hold AbbVie stock. Eric Rovner has served on an advisory board for Allergan/AbbVie and as a study participant and central urodynamics reader for prior Allergan onabotulinumtoxinA studies. 

Funding/Support and role of the sponsor: Allergan (now AbbVie) funded this study and contributed to the study design, collection, analysis, and interpretation of the data, and review and approval of the manuscript for publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship."